Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval

 
• By Dexter Jie Yan
  
stroke.jpg
Sanbexin sublingual significantly improved the ratio of the AIS patients with good functional outcomes by roughly 10 percentage points on day 90.

More from New Products

More from Scrip